Thilo Schroeder

This profile gathers the share dealings of Thilo Schroeder across 3 companies, led by PMV Pharmaceuticals, Inc., Revolution Medicines, Inc. and ARS Pharmaceuticals, Inc. Between 18 February 2020 and 5 December 2024, the trades on record add up to 142 filings.

Both buying and selling appear: 38 purchases worth €118.4M, against 97 sales worth €32.4M. Taken together, the purchases exceed the sales by €86.0M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants. So far in 2024, the count stands at 2 purchases and no sales.

A typical purchase (the median) is worth €854k. On 2 out of 35 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 35 purchases with a full 90-day history, the hit rate stands at 26% and the median 90-day move at -10.4%. This is a record of the past, not a forecast.

On 9 December 2024 came the latest disclosure, an open-market purchase for €33.3M in Revolution Medicines, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.